Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast Cancer

Minatani, Naoko; Waraya, Mina; Yamashita, Keishi; Kikuchi, Masatoshi; Ushiku, Hideki; Kojo, Ken; Ema, Akira; Nishimiya, Hiroshi; Kosaka, Yoshimasa; Katoh, Hiroshi; Sengoku, Norihiko; Tanino, Hirokazu; Sidransky, David; Watanabe, Masahiko

doi:10.1371/journal.pone.0144862

Cited by 32 publications

(44 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…36,37 Interestingly, in primary breast cancer, CDO1 hypermethylation did not correlate significantly with markers of tumor progression such as TNM factors, while CDO1 hypermethylation was the strongest independent prognostic factor. 34 Importantly, the prognostic relevance of CDO1 methylation was confirmed even in a prospective nationwide cohort study in the Netherlands of patients with renal cell carcinoma. 40 These findings suggest that the methylation status of the CDO1 gene could be used as a prognostic marker in various human cancers.…”

Section: The B E S T Performan Ce a S An Epi G Ene Ti C C An Cer B mentioning

confidence: 89%

“…Cases with CDO1 hypermethylation also showed poorer prognosis than those with hypomethylation in primary breast, prostate, colorectal, gallbladder and esophageal cancers . Interestingly, in primary breast cancer, CDO1 hypermethylation did not correlate significantly with markers of tumor progression such as TNM factors, while CDO1 hypermethylation was the strongest independent prognostic factor . Importantly, the prognostic relevance of CDO1 methylation was confirmed even in a prospective nationwide cohort study in the Netherlands of patients with renal cell carcinoma .…”

Section: The Best Performance As An Epigenetic Cancer Biomarker: Cdo1mentioning

confidence: 92%

“…Cases with CDO1 hypermethylation also showed poorer prognosis than those with hypomethylation in primary breast, 34 prostate, 41 colorectal, 38 gallbladder 44 and esophageal cancers. 36,37 Interestingly, in primary breast cancer, CDO1 hypermethylation did not correlate significantly with markers of tumor progression such as TNM factors, while CDO1 hypermethylation was the strongest independent prognostic factor.…”

Section: The B E S T Performan Ce a S An Epi G Ene Ti C C An Cer B mentioning

confidence: 93%

“…Since 2010, the frequent hypermethylation of the CDO1 gene has been reported in primary breast, 33,34 lung, 19 biliary tract, 35 esophageal squamous cell carcinoma (SCC) 36 and adenocarcinoma, 37 gastric, 19 colorectal, 19,38 bladder, 19 penile (SCC), 39 kidney, 40 prostate, 41 endometrial, 42 pancreatic 43 and gallbladder cancer. 44 The frequencies of the aberrations in CDO1 methylation in these cancers are high ( Figure 3A).…”

Section: The B E S T Performan Ce a S An Epi G Ene Ti C C An Cer B mentioning

confidence: 99%

See 3 more Smart Citations

Epigenetic biomarkers of promoter DNA methylation in the new era of cancer treatment

et al. 2018

Self Cite

View full text Add to dashboard Cite

Promoter DNA methylation, which occurs on cytosine nucleotides across CpG islands, results in gene silencing and represents a major epigenetic alteration in human cancer. Methylation‐specific PCR can amplify these modifications as markers in cancer cells. In the present work, we rigorously review the published literatures describing DNA methylation in the promoters of critical tumor suppressor genes; detection of promoter DNA methylation in various body fluids permits early detection of cancer cells during perioperative courses of clinical treatment. The latest whole‐genome comprehensive explorations identified excellent epigenetic biomarkers that could be detected at high frequency with high specificity; these biomarkers, which are designated highly relevant methylation genes (HRMG), permit the discrimination of tumor tissues from the corresponding normal tissues; these markers are also associated with unique cancer phenotypes, including dismal prognosis. In humans, HRMG include the CDO1,GSHR,RASSF1 and SFRP1 genes, with these markers permitting discrimination depending on the organs tested. The combination of several HRMG increased the early detection of cancer and exhibited reliable surveillance potential in human body fluids. Cancer clinics using such epigenetic biomarkers are entering a new era of enhanced decision‐making with the potential for improved cancer prognosis.

show abstract

Section: The B E S T Performan Ce a S An Epi G Ene Ti C C An Cer B mentioning

confidence: 89%

Section: The Best Performance As An Epigenetic Cancer Biomarker: Cdo1mentioning

confidence: 92%

Section: The B E S T Performan Ce a S An Epi G Ene Ti C C An Cer B mentioning

confidence: 93%

Section: The B E S T Performan Ce a S An Epi G Ene Ti C C An Cer B mentioning

confidence: 99%

See 2 more Smart Citations

Epigenetic biomarkers of promoter DNA methylation in the new era of cancer treatment

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…CDO1 plays a role as a tumor suppressor gene. As it is a methylation‐specific gene in human cancer, CDO1 methylation has been recently reported in a variety of cancers, such as esophageal, lung, gastric, breast, biliary tract, colorectal, kidney, prostate, bladder, penile, and uterine cancers . However, there has been no report on the involvement of CDO1 in PDAC.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer

et al. 2019

Self Cite

View full text Add to dashboard Cite

DNA markers for pancreatic ductal adenocarcinoma (PDAC) are urgently needed for detection of minimally invasive disease. The epigenetic relevance of the cysteine dioxygenase 1 gene (CDO1) has been never investigated in PDAC. Three studies, including cellular experiments, tissue validation, and pilot testing for pancreatic cytology, were carried out. Promoter DNA methylation value (MV) of CDO1 was quantified by quantitative methylation‐specific PCR. CDO1 expression was consistent with its promoter DNA methylation in 7 PDAC cell lines. In 160 retrospectively collected primary PDAC tumor tissues, MV was significantly higher compared to the corresponding noncancerous pancreas (area under the receiver operating characteristic curve [AUC] = 0.97, P < .0001), and CDO1 hypermethylation was highly specific to PDAC tumor tissues. CDO1 hypermethylation group (MV over 19) was significantly associated with diverse prognostic factors in PDAC. Surprisingly, it was significantly higher in prospectively collected PDAC cytology samples (n = 37), including both pancreatic juice (n = 12) and endoscopic ultrasound‐fine needle aspiration (EUS‐FNA) cytology (n = 25) compared to pancreatic benign diseases (AUC = 0.96, P < .0001). Detection of PDAC was confirmed by DNA testing in 35 of 37 patients (95% sensitivity); thus, it was more sensitive than cytology (33%) or EUS‐FNA cytology (88%). Promoter DNA methylation of CDO1 is extremely specific for PDAC tumors, and accumulates with PDAC tumor progression. It could be a definitive diagnostic marker of PDAC in pancreatic juice or EUS‐FNA cytology.

show abstract

Identification of aberrantly methylated differentially expressed genes and associated pathways in endometrial cancer using integrated bioinformatic analysis

Liu

Wan

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

Endometrial cancer (EC) is a fatal female reproductive tumor. Bioinformatic tools are increasingly developed to screen out molecular targets related to EC. In this study, GSE17025 and GSE40032 were obtained from Gene Expression Omnibus (GEO). “limma” package and Venn diagram tool were used to identify hub genes. FunRich was used for functional analysis. Retrieval of Interacting Genes Database (STRING) was used to analyze protein‐protein interaction (PPI) complex. Cancer Genome Atlas (TCGA), GEPIA, immunohistochemistry staining, and ROC curve analysis were carried out for validation. Univariate and multivariate regression analyses were performed to predict the risk score. Compound muscle action potential (CMap) was used to find potential drugs. GSEA was also done. We retrieved seven oncogenes which were upregulated and hypomethylated and 12 tumor suppressor genes (TSGs) which were downregulated and hypermethylated. The upregulated and hypomethylated genes were strikingly enriched in term “immune response” while the downregulated and hypermethylated genes were mainly focused on term “aromatic compound catabolic process.” TCGA and GEPIA were used to screen out EDNRB, CDO1, NDN, PLCD1, ROR2, ESPL1, PRAME, and PTTG1. Among them, ESPL1 and ROR2 were identified by Cox regression analysis and were used to construct prognostic risk model. The result showed that ESPL1 was a negative independent prognostic factor. Cmap identified aminoglutethimide, luteolin, sulfadimethoxine, and maprotiline had correlation with EC. GSEA results showed that “hedgehog signaling pathway” was enriched. This research inferred potential aberrantly methylated DEGs and dysregulated pathways may participate in EC development and firstly reported eight hub genes, including EDNRB, CDO1, NDN, PLCD1, ROR2, ESPL1, PRAME, and PTTG1 that could be used to predict EC prognosis. Aminoglutethimide and luteolin may be used to fight against EC.

show abstract

Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast Cancer

Cited by 32 publications

References 30 publications

Epigenetic biomarkers of promoter DNA methylation in the new era of cancer treatment

Epigenetic biomarkers of promoter DNA methylation in the new era of cancer treatment

Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer

Identification of aberrantly methylated differentially expressed genes and associated pathways in endometrial cancer using integrated bioinformatic analysis

Contact Info

Product

Resources

About